Your session is about to expire
← Back to Search
Genetic Testing for Lung Cancer
This trial looks at whether genetic testing can help select the best treatment for patients with early-stage non-small cell lung cancer.
- Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 453 Patients • NCT03066778
Find a Location
Who is running the clinical trial?
- You have had surgery to remove your non-small cell lung cancer completely, with no remaining cancer cells. If you have squamous cell carcinoma, you can participate as long as you haven't received any additional treatment after surgery.You have not received any previous treatments that target specific gene mutations or immune checkpoints.You have squamous cell carcinoma, but you haven't received any additional treatment after your initial therapy.You have a type of lung cancer called non-small cell lung cancer, specifically adenocarcinoma or adenosquamous histology.You have a type of cancer called squamous cell carcinoma.You have previously had surgery to remove lung cancer, but it has not returned.
- Group 1: EA5142 Arm I (nivolumab)
- Group 2: A081801 Arm A (platinum doublet, observation)
- Group 3: A081801 Arm C (platinum doublet, combination pembrolizumab)
- Group 4: A081105 Arm C (unblinded erlotinib hydrochloride)
- Group 5: A081105 Arm B (placebo)
- Group 6: E4512 Arm B (observation)
- Group 7: EA5142 Arm II (observation)
- Group 8: E4512 Arm A (crizotinib)
- Group 9: A081801 Arm B (platinum doublet, sequential pembrolizumab)
- Group 10: A081105 Arm D (observation)
- Group 11: A081105 Arm A (blinded erlotinib hydrochloride)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is the clinical trial accepting at this time?
"That is accurate. As per data hosted on clinicaltrials.gov, this medical trial was first posted on August 18th 2014 and it is still actively recruiting patients; the study aims to enrol 8300 participants from 100 different sites."
Are there opportunities for enrolment in this experiment yet?
"Affirmative, clinicaltrials.gov indicates that this research is actively enrolling participants. It was first advertised on August 18th 2014 and the most recent update came December 1st 2022. The goal of this trial is to recruit 8300 patients from 100 different sites."
In what areas are the trials of this experiment being conducted?
"This trial is primarily based at Aurora Health Care Germantown Health Center in Wisconsin, Aurora Cancer Care-Grafton in Minnesotaa Cancer Care-Grafton in Minnesota and Marshfield Medical Center-River Region in Iowa. An additional 100 sites are also participating across the country."
Can you provide a catalogue of experiments utilizing Pembrolizumab?
"Originally studied at the City of Hope Comprehensive Cancer Center in 1997, pembrolizumab has now been explored through 3729 completed studies. Currently, 3179 active trials are being conducted with a substantial amount of this research taking place in Germantown, Wisconsine Cancer Center in 1997, pembrolizumab has now been explored through 3729 completed studies. Currently, 3179 active trials are being conducted with a substantial amount of this research taking place in Germantown, Wisconsin."
Share this study with friends